In your words Massey, "spot on"!
But, given the rising publicity in this cell stem sphere, and the fact that it is a back door listing of Cynata, investors will be all over it upon relisting I think to establish long term positions.
Also, with the number of shares consolidated from 640m down to 57m post consolidation, the shares will be more tightly held i would imagine. Ditto the 17m options.
Last post for awhile.
GLAll.
